A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

Trial Profile

A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Erythema
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2016 According to an Allergan media release, the NDA filing for oxymetazoline HCl cream 1.0% for the treatment of persistent facial erythema (redness) associated with rosacea in adults has been accepted by the US FDA for standard review. Allergan expects the Prescription Drug User Fee Act (PDUFA) date to be in the first half of 2017. The NDA submission was based on data collected from two phase 3 pivotal clinical trials of a 29-day treatment duration and a 1-year open label clinical trial.
    • 19 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top